What is Spero?
Headquartered in Cambridge, Massachusetts, Spero Therapeutics is a biopharmaceutical enterprise currently undergoing a significant strategic realignment. Having established its reputation through the development of Utebzi, the first oral carbapenem for urinary tract infections, the company is now pivoting its primary focus toward immunology and inflammation. This transition is anchored by the development of SP001, a Phase 2-ready anti-CD40L antibody designed to address IgG4-related disease. By divesting and monetizing legacy assets, Spero is positioning itself as a specialized player in the immunology space, aiming to address significant unmet medical needs through targeted therapeutic interventions.
How much funding has Spero raised?
Spero has raised a total of $105M across 1 funding round:
Debt
$105M
Debt (2026): $105M with participation from HealthCare Royalty Management
Key Investors in Spero
HealthCare Royalty Management
HealthCare Royalty Management is a specialized investment firm that provides non-dilutive capital solutions to biopharmaceutical companies by acquiring royalty interests in commercial-stage assets.
What's next for Spero?
Looking ahead, Spero is poised to accelerate the clinical development of its immunology pipeline. The recent capital injection provides the firm with the operational flexibility to advance SP001 through critical trial milestones without the immediate need for dilutive equity financing. Investors should monitor the company's progress in Phase 2 trials, as the successful validation of its anti-CD40L antibody platform will be the primary driver of long-term shareholder value. Furthermore, the company's ability to maintain its lean operational structure while scaling its R&D efforts will be essential as it navigates the competitive landscape of autoimmune disease therapeutics.
See full Spero company page
